Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial

Journal of Clinical Epidemiology

Volumn 61, Issue 1, 2008, Pages 87.e1-87.e9

  Eg Hansen, Ann Brit ^a,b   Gerstoft, Jan ^b   Kirk, Ole ^c   Mathiesen, Lars ^c   Pedersen, Court ^a   Nielsen, Henrik ^d   Jensen Fangel, Søren ^e   Sørensen, Henrik Toft ^e,f   Obel, Niels ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f BOSTON UNIVERSITY   (United States)

Author keywords

Highly active antiretroviral therapy; HIV; Observational study; Pragmatic trial; Randomized controlled trial; Trial effect

Indexed keywords

EID: 36849064843     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2007.04.001     Document Type: Article

References (34)

1. Braunholtz D.A., Edwards S.J., and Lilford R.J. Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". J Clin Epidemiol 54 (2001) 217-224
2. Peppercorn J.M., Weeks J.C., Cook E.F., and Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 363 (2004) 263-270
3. Munoz A., Gange S.J., and Jacobson L.P. Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. AIDS 14 (2000) 754-756
4. Park-Wyllie L.Y., Scalera A., Tseng A., and Rourke S. High rate of discontinuations of highly active antiretroviral therapy as a result of antiretroviral intolerance in clinical practice: missed opportunities for adherence support?. AIDS 16 (2002) 1084-1086
5. Vist G.E., Hagen K.B., Devereaux P.J., Bryant D., Kristoffersen D.T., and Oxman A.D. Systematic review to determine whether participation in a trial influences outcome. BMJ 330 (2005) 1175-1179
6. Wei L., Ebrahim S., Bartlett C., Davey P.D., Sullivan F.M., and Macdonald T.M. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 330 (2005) 821-824
7. Benson K., and Hartz A.J. A comparison of observational studies and randomized, controlled trials. N Engl J Med 342 (2000) 1878-1886
8. Ioannidis J.P., Haidich A.B., Pappa M., Pantazis N., Kokori S.I., Tektonidou M.G., et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 286 (2001) 821-830
9. Madge S., Mocroft A., Wilson D., Youle M., Lipman M.C., Phillips A., et al. Participation in clinical studies among patients infected with HIV-1 in a single treatment centre over 12 years. HIV Med 1 (2000) 212-218
10. Moore D.A., Goodall R.L., Ives N.J., Hooker M., Gazzard B.G., and Easterbrook P.J. How generalizable are the results of large randomized controlled trials of antiretroviral therapy?. HIV Med 1 (2000) 149-154
11. Gifford A.L., Cunningham W.E., Heslin K.C., Andersen R.M., Nakazono T., Lieu D.K., et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med 346 (2002) 1373-1382
12. Kirk O., Gerstoft J., Pedersen C., Nielsen H., Obel N., Katzenstein T.L., et al. Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort. HIV Med 2 (2001) 43-51
13. Dunn D., Babiker A., Hooker M., and Darbyshire J. The dangers of inferring treatment effects from observational data: a case study in HIV infection. Control Clin Trials 23 (2002) 106-110
14. Phillips A.N., Grabar S., Tassie J.M., Costagliola D., Lundgren J.D., and Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 13 (1999) 2075-2082
15. Katzenstein T.L., Kirk O., Pedersen C., Lundgren J.D., Nielsen H., Obel N., et al. The Danish Protease Inhibitor Study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection. J Infect Dis 182 (2000) 744-750
16. Kirk O., Katzenstein T.L., Gerstoft J., Mathiesen L., Nielsen H., Pedersen C., et al. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. AIDS 13 (1999) F9-F16
17. Kirk O., Lundgren J.D., Pedersen C., Mathiesen L.R., Nielsen H., Katzenstein T.L., et al. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors. Antivir Ther 8 (2003) 595-602
18. Gerstoft J., Kirk O., Obel N., Pedersen C., Mathiesen L., Nielsen H., et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 17 (2003) 2045-2052
19. Lohse N., Hansen A., Jensen-Fangel S., Kronborg G., Kvinesdal B., Larsen C.S., et al. Demographics of HIV-1 infection in Denmark: results from The Danish HIV Cohort Study. Scand J Infect Dis 37 (2005) 338-343
20. Andersen T.F., Madsen M., Jørgensen J., Mellemkjær L., and Olsen J.H. The Danish Hospital Register: a valuable source of data for modern health sciences. Dan Med Bull 46 (1999) 263-268
21. Jensen-Fangel S., Pedersen L., Pedersen C., Larsen C.S., Tauris P., Moller A., et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis 35 (2002) 1541-1548
22. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 (1987) 373-383
23. Sundararajan V., Henderson T., Perry C., Muggivan A., Quan H., and Ghali W.A. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 57 (2004) 1288-1294
24. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 79 (1989) 340-349
25. The Consort Statement. Available at. http://www.consort-statement.org/ Accessed March 21, 2007
26. Gartlehner G., Hansen R.A., Nissman D., Lohr K.N., and Carey T.S. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol 59 (2006) 1040-1048
27. Rothwell P.M. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet 365 (2005) 82-93
28. Rothman K.J. Epidemiology. An introduction (2002), Oxford University Press, Oxford
29. Sorensen H.T., Lash T.L., and Rothman K.J. Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology 44 (2006) 1075-1082
30. Concorde. MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 343 (1994) 871-881
31. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet 348 (1996) 283-291
32. Nettles R.E., Kieffer T.L., Kwon P., Monie D., Han Y., Parsons T., et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 293 (2005) 817-829
33. Opravil M., Hirschel B., Lazzarin A., Furrer H., Chave J.P., Yerly S., et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 185 (2002) 1251-1260
34. Walmsley S., Bernstein B., King M., Arribas J., Beall G., Ruane P., et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346 (2002) 2039-2046